Bibliographic details
Strom O, Jonsson B, Kanis JA. Intervention thresholds for denosumab in the UK using a FRAX-based cost-effectiveness analysis. Osteoporosis International 2013; 24(4): 1491-1502
MeSH
Aged; Aged, 80 and over; Alendronate /economics /therapeutic use; Algorithms; Antibodies, Monoclonal, Humanized /economics /therapeutic use; Bone Density Conservation Agents /economics /therapeutic use; Cost-Benefit Analysis; Denosumab; Drug Costs /statistics & Etidronic Acid /analogs & Female; Great Britain /epidemiology; Health Care Costs /statistics & Humans; Middle Aged; Models, Econometric; Osteoporosis, Postmenopausal /drug therapy /economics; Osteoporotic Fractures /economics /epidemiology /prevention & Quality of Life; RANK Ligand /antagonists & Risedronate Sodium; Risk Assessment /methods; Thiophenes /economics /therapeutic use; control; derivatives /therapeutic use; inhibitors; numerical data; numerical data